0001209191-20-024476.txt : 20200415 0001209191-20-024476.hdr.sgml : 20200415 20200415161524 ACCESSION NUMBER: 0001209191-20-024476 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200413 FILED AS OF DATE: 20200415 DATE AS OF CHANGE: 20200415 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silva Paul M CENTRAL INDEX KEY: 0001446372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20793853 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-13 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001446372 Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP & Controller Common Stock 2020-04-13 4 M 0 859 90.29 A 15791 D Common Stock 2020-04-13 4 S 0 50 244.09 D 15741 D Common Stock 2020-04-13 4 S 0 150 245.62 D 15591 D Common Stock 2020-04-13 4 S 0 150 247.18 D 15441 D Common Stock 2020-04-13 4 S 0 150 248.96 D 15291 D Common Stock 2020-04-13 4 S 0 193 250.29 D 15098 D Common Stock 2020-04-13 4 S 0 166 252.26 D 14932 D Common Stock 169 I 401(k) Stock Option (Right to Buy) 90.29 2020-04-13 4 M 0 859 0.00 D 2026-07-11 Common Stock 859 860 D Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $245.62 (range $245.31 to $246.00). Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $247.18 (range $246.88 to $247.44). Open market sales reported on this line occurred at a weighted average price of $248.96 (range $248.75 to $249.30). Open market sales reported on this line occurred at a weighted average price of $250.29 (range $249.95 to $250.54). Open market sales reported on this line occurred at a weighted average price of $252.26 (range $251.99 to $252.85). The option vests in 16 quarterly installments from 07/12/2016. Omar White, Attorney-in-Fact 2020-04-15